CJC1295(withoutDAC)5MG+IPA5MG

This combination is studied to examine how growth hormone secretion is stimulated through two distinct signaling pathways:

• CJC-1295 without DAC: Acts as a GHRH receptor agonist, activating adenylyl cyclase and cAMP-dependent pathways on pituitary somatotrophs
• Ipamorelin: Acts as a GHRP-receptor agonist (GHS-R agonist) through calcium-dependent signaling mechanisms, demonstrating selectivity for GH release without affecting ACTH or cortisol levels

The synergistic combination leverages complementary mechanisms: cAMP activation (CJC-1295) and calcium-dependent signaling (Ipamorelin) to produce amplified GH secretion through multi-pathway activation.

• High-purity peptides provided in separate 5 mg vials for precise dosing in research.
• Lyophilized powder form for enhanced stability and easy reconstitution.
• Synergistic Functionality: Combines two peptides that stimulate growth hormone through different receptors.
• Metabolic Regulation: Used in studies exploring endogenous growth hormone stimulation.
• Cellular Impact: Supports research on tissue repair, cell regeneration, and recovery.
• Stable when stored correctly at low temperatures.

This combination is used to study how growth hormone secretion is stimulated through two distinct pathways. CJC-1295 acts like GHRH, while Ipamorelin activates ghrelin receptors.

Research explores the peptides’ roles in metabolic regulation, tissue growth, and endocrine modulation, with a focus on muscle and bone biology and potential applications in aging-related processes.

In preclinical and laboratory studies, dosing protocols for CJC-1295 without DAC and Ipamorelin combinations typically employ:

• CJC-1295 without DAC: 100–300 mcg per injection, administered 2–3 times daily to maintain elevated GH levels (short 30-minute half-life)​
• Ipamorelin: 200–300 mcg per injection, administered daily or 2–3 times daily depending on study protocol​
• Combination approach: Both peptides are often co-administered to maximize synergistic GH release through dual-pathway activation​

Published single-dose rodent studies have evaluated CJC-1295 at 30–60 µg/kg; however, sustained research applications typically use the absolute dosages listed above.​

Research observations include:

• Elevated growth hormone (GH) levels with enhanced pulsatility​
• Increased insulin-like growth factor 1 (IGF-1) production
• Enhanced tissue repair and recovery markers
• Preserved hormone selectivity (ipamorelin does not increase ACTH or cortisol)​

These observations are based on animal studies, and there is no clinical data on human dosing or safety/efficacy.​

• Storage: Store lyophilized peptides at –20°C or below in a dry, light-protected
• After reconstitution, store at 2–8°C and use within 5–7 days.
• Avoid freeze-thaw cycles to protect peptide integrity.
• Handle using aseptic techniques and proper laboratory safety protocols.

This product is intended for laboratory research use only and is not approved for human or veterinary use.